Fig. 3: BRD4 inhibition and antitumor effect in vitro. | Nature Communications

Fig. 3: BRD4 inhibition and antitumor effect in vitro.

From: MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

Fig. 3

a WB analyses of BRD4 inhibition and EMT downregulation on 4T1 cells. The G1–G6 represent control, dBET6&Ce6 + L, CFMPD + L, dBET6@CPD + L, dBET6@CFPD + L, and dBET6@CFMPD + L, respectively. b PD-L1 expression of 4T1 cells treated with different formulations. c Detection of intracellular ROS generation by flow cytometry (n = 3 independent experimental cell lines). MTT assay after incubating 4T1 cells with parent nanoparticles (d) and BET6-loaded nanoparticles (e). n = 3 independent cell lines. f Apoptosis assay of 4T1 cells treated with various formulations. g Statistical results of apoptosis analysis (n = 3 independent cell lines). h Live/dead double staining of 4T1 cells incubated with different preparations (scale bar = 100 μm). All data are presented as mean ± SD. Two-tailed Student’s t test and One-way analysis of variance (ANOVA) with a Tukey post hoc test were used for the statistical comparison between the two groups and among multiple groups, respectively. A significant difference was considered when the p value was <0.05. Source data are provided as a Source Data file.

Back to article page